Transplantation for hilar cholangiocarcinoma | Zendy

Heimbach Julie K. | Zendy; Haddock Michael G. | Zendy; Alberts Steven R. | Zendy; Nyberg Scott L. | Zendy; Ishitani Michael B. | Zendy; Rosen Charles B. | Zendy; Gores Gregory J. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Transplantation for hilar cholangiocarcinoma

Author(s) -

Heimbach Julie K.,

Haddock Michael G.,

Alberts Steven R.,

Nyberg Scott L.,

Ishitani Michael B.,

Rosen Charles B.,

Gores Gregory J.

Publication year - 2004

Publication title -

liver transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.814

H-Index - 150

eISSN - 1527-6473

pISSN - 1527-6465

DOI - 10.1002/lt.20266

Subject(s) - medicine , liver transplantation , primary sclerosing cholangitis , intrahepatic cholangiocarcinoma , transplantation , fluorescence in situ hybridization , lesion , survival rate , gastroenterology , pathology , gene , disease , biochemistry , chemistry , chromosome

Key Points 1 Patients with primary sclerosing cholangitis (PSC) have a 8 to 12% risk of developing cholangiocarcinoma (CCA). 2 Cytologic techniques for aneuploidy such as digital image analysis and fluorescence in situ hybridization increase the detection rate for CCA. 3 Survival following resection for CCA is 20% to 40% at 5 years. 4 Survival following liver transplantation for unresectable, perihilar CCAs, mass lesion if present <3 cm, is greater than 80% at 5 years. 5 Patients with intrahepatic CCAs are not eligible for liver transplantation. (Liver Transpl 2004;10:S65–S68.)

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research